Panelists discuss City of Hope’s multidisciplinary approach, highlighting pharmacists providing medication guidance, social ...

Panelists share that despite initial emotional challenges, multiple myeloma treatment with targeted combination therapies was ...

Hope S. Rugo, MD, FASCO, emphasized the importance of educating patients about proactive rash and diarrhea management while taking PI3K/AKT inhibitors.

Establishing routine early on helps proactively manage adverse effects associated with CDK4/6 inhibitors, says Kimberly ...

Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for ...

The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell ...

A generic version of ibrutinib was granted tentative approval by the FDA for use in CLL and SLL with 17p deletion and ...

Panelists discuss the critical role of patient education and multidisciplinary coordination in managing immunotherapy side ...

Panelists discuss updated MonumenTAL-1 trial data demonstrating high response rates and prolonged survival with ...

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Panelists discuss the importance of vigilant, patient-centered monitoring for metastatic melanoma patients with high disease ...

Panelists discuss updated safety findings from GPRC5D-targeted bispecific therapy in relapsed/refractory multiple myeloma, ...